Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510351 | 0.79 | FKBP1A (0.52) | ADAM17ROCK2RIPK1SCD5 | |
| SCHEMBL19151688 | 0.77 | ADAM17 (0.54) | ADAM17DRD2ROCK2OPRM1OPRK1 | |
| SCHEMBL24775502 | 0.77 | DRD2 (0.50) | DRD2CHRNA7THRBKDM4EALDH1A1 | |
| SCHEMBL7201896 | 0.73 | CHRNA1 (0.47) | ADAM17CHRNA7ROCK2KDM4EALDH1A1 | |
| SCHEMBL19275752 | 0.73 | THRB (0.56) | DRD2CHRNA7OPRM1OPRK1THRB | |
| SCHEMBL23449208 | 0.73 | KDM4E (0.47) | DRD2CHRNA7ROCK2THRBKDM4E | |
| SCHEMBL28168304 | 0.72 | ROCK2 (0.56) | ADAM17DRD2ROCK2OPRM1OPRK1 | |
| SCHEMBL18520901 | 0.71 | ROCK2 (0.45) | ADAM17DRD2ROCK2OPRM1OPRK1 | |
| SCHEMBL13162095 | 0.70 | CHRNB4 (0.62) | DRD2CHRNA7ALDH1A1LMNA | |
| SCHEMBL21392838 | 0.70 | ROCK2 (0.52) | ADAM17ROCK2OPRM1OPRK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290612-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | DAVID WEINSTEIN CONSULTING INC (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290612-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | FKBP4, FKBP1B, FKBP3 | ADAM17 2376/4885DRD2 4881/4885CHRNA7 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.